Who We Are

Member Companies

Board Members

Kenneth Bradley, Ph.D.

VP, Global Head,
Infectious Disease Discovery at Roche pharmaceutical Research and Early Development (pRED)

Margaret Chu-Moyer, Ph.D.

VP, Research and Head of Small Molecule Therapeutic Discovery (SMTD)
Amgen

Tomas Cihlar, Ph.D.

Senior Vice President of Virology
Gilead Sciences

Lydia Ogden, Ph.D.

Secretary, INTREPID Alliance
Health Policy and Engagement
Johnson & Johnson

Michelle A. Parks, J.D.

Head, Technology Licensing & Collaborations
AbbVie

Kumar Singh Saikatendu, Ph.D.

Head, Lipid Nanoparticle Platform
Takeda Pharmaceuticals

Sujata Vaidyanathan, Ph.D.

Development Unit Head
In-Market Brands and Global Health
Novartis

Officers

James Anderson, M.A., MBA

Chair, INTREPID Alliance
Executive Director, Global Health
IFPMA

James Bergin, B.Leg.S, LL.M.

Treasurer, INTREPID Alliance
Vice President Law
Johnson & Johnson Global Public Health

Lydia Ogden, Ph.D.

Secretary, INTREPID Alliance
Health Policy and Engagement
Johnson & Johnson

Scientific Advisory Board Chair

Ruxandra Draghia-Akli, M.D., Ph.D.

Chair, INTREPID Alliance Scientific Advisory Board

Science Working Group Co-Leads

Tomas Cihlar, Ph.D.

Senior Vice President of Virology
Gilead Sciences

Kenneth Bradley, Ph.D.

VP, Global Head,
Infectious Disease Discovery at Roche pharmaceutical Research and Early Development (pRED)

Policy Working Group Lead

Lydia Ogden, Ph.D.

Health Policy and Engagement
Johnson & Johnson

Advisors

Christopher D. Comeau

Partner
Ropes & Gray LLP

Elliott Levy, M.D.

Co-founder
INTREPID

Winsome Cheung

Partner
Covington

Sibel Yilmaz

Partner
Covington

Secretariat

Nina M. Hill, Ph.D.

Nina serves as the head of the Secretariat of the INTREPID Alliance with the responsibility of implementing the activities endorsed by the Board.

John C. Pottage, Jr., M.D.

Lead Scientific Consultant

Jim Demarest, Ph.D.

Scientific Consultant

The INTREPID Alliance, Inc is a 501(c)(6) organization.

The Board, consisting of 7 founding member companies was elected on May 19, 2022, and terms of reference were agreed.

For more information and membership inquiries contact [email protected].